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Abstract
Background: QUADOMICS is an adaptation of QUADAS (a quality assessment tool for use in systematic reviews of
diagnostic accuracy studies), which takes into account the particular challenges presented by ‘-omics’ based technologies.
Our primary objective was to evaluate the applicability and consistency of QUADOMICS. Subsequently we evaluated and
describe the methodological quality of a sample of recently published studies using the tool.
Methodology/Principal Findings: 45‘-omics’- based diagnostic studies were identified by systematic search of Pubmed
using suitable MeSH terms (‘‘Genomics’’, ‘‘Sensitivity and specificity’’, ‘‘Diagnosis’’). Three investigators independently
assessed the quality of the articles using QUADOMICS and met to compare observations and generate a consensus.
Consistency and applicability was assessed by comparing each reviewer’s original rating with the consensus.
Methodological quality was described using the consensus rating. Agreement was above 80% for all three reviewers.
Four items presented difficulties with application, mostly due to the lack of a clearly defined gold standard. Methodological
quality of our sample was poor; studies met roughly half of the applied criteria (mean 6 sd, 54.7618.4%). Few studies were
carried out in a population that mirrored the clinical situation in which the test would be used in practice, (6, 13.3%); none
described patient recruitment sufficiently; and less than half described clinical and physiological factors that might influence
the biomarker profile (20, 44.4%).
Conclusions: The QUADOMICS tool can consistently be applied to diagnostic ‘-omics’ studies presently published in
biomedical journals. A substantial proportion of reports in this research field fail to address design issues that are
fundamental to make inferences relevant for patient care.
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Introduction
Technological advances in the past 20 years have permitted
large-scale parallel measurements of biochemical and cellular
constituents for study as a unified whole, spurring what may be
referred to as the ‘-omics’ revolution. [1–3] By adding the suffix ‘-
omics’, we can refer to the comprehensive study of almost any
cellular constituent. For instance, transcriptomics refers to analysis
of total mRNA expression and proteomics refers to the analysis of
the proteome, the total protein content. The coupling of these high
throughput technologies with computer-assisted discrimination
systems may substantially influence the future of clinical diagnosis,
leading to diagnostic tests based on multi-marker patterns,
biomarker profiles or signatures, rather than on a single alteration
[1,4].
Despite rigorous and vigorous promotion of ‘-omics’ based
technologies for diagnosis of human diseases, few of the many tests
proposed have been introduced into clinical practice with clearly
documented clinical benefits. [5–7] Analysis and interpretation of
the diagnostic capacity of ‘-omics’ based technologies has
presented unique challenges, [8] and reproducing the initial
claims of diagnostic accuracy in independent populations has often
proved complex. [9,10] The apparent -but in fact artifactual-
power to discriminate between diagnostic groups using ‘-omics’
technologies may actually be due to methodological features of the
studies; most notably, differences in the pre-analytical procedures,
[11] in the clinical or pathophysiological characteristics of the
patients who provided the biological samples, [12–14] or simply
chance. [15,16] Consequently, in ‘-omics’ studies investigators
must consider the potential genetic variation between different
individuals, or how certain physiological characteristics (disease
pathophysiology, stress, menstruation) could influence the serum
protein profile of study participants. When designing and
analysing their experiments, investigators must also consider the
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by ‘-omics’ techniques, such as RNA degradation and repetitive
freezing cycles. Furthermore, the tendency to develop or ‘discover’
the biomarker patterns using the available data, [17] rather than
having a predefined hypothesis as to which biomarkers are likely to
be involved, make these studies susceptible to overfitting [15,16]
(i.e., the apparent discrimination is due to chance and results
cannot be reproduced in other populations). Additionally, ‘-omics’
technologies may be subject to limitations common to all
diagnostic research. For example, one common problem in study
design is the tendency to collect two groups of patients for
discrimination separately (in what can be considered a diagnostic
case-control study), instead of prospectively recruiting a group of
patients with clinical suspicion of the disease under question, and
then using the ‘-omics’ technology to discriminate between
patients who are finally diagnosed with the disease and those
who are not. [18,19]
Achievement of all legitimate clinical and commercial interests
requires that the provision of ‘-omics’-based diagnostic services be
evidence based. [20] Tools for evaluating the quality of diagnostic
research reports included in a systematic review, such as
QUADAS, [21] have made a considerable impact in promoting
evidence based diagnosis. Nevertheless, there is some concern that
quality appraisal tools generic to all diagnostic tests may not be
sufficiently adequate for this complex field, as such tools do not
address the issues specific to the ‘-omics’ field previously
mentioned. Consequently, we proposed an adaptation to the
QUADAS guideline to take into account the particular challenges
presented by ‘-omics’ based technologies. QUADOMICS [22]
incorporates four new items addressing the type of sample used,
differences in pre-analytical conditions, the clinical and physio-
logical characteristics of the patients providing biological samples,
and overfitting. Furthermore, it calls for users to classify each study
into one of four phases of biomarker validation, according to the
population in which the study is carried out. [23–25] In the first
three phases a case control design may be used, and the objective
could be to show discrimination between patients with overt
disease and healthy individuals, to challenge the test with
competing diagnoses, diverse co-morbidities or varying levels of
disease severity, or to evaluate changes in diagnostic accuracy
according to particular patient characteristics. However, in the
fourth phase of evaluation, the test should be evaluated in a
prospective series of individuals that reflect, with the maximum
degree of fidelity, the clinical or public health setting where the test
would be used.The evaluation of study phase was incorporated
into QUADOMICS to increase recognition of issues related to the
spectrum of patients studied, [26] and the requirements for
synthesising results from studies in different phases when
performing a meta-analysis. [27,28]
As with any quality appraisal tool, it is essential that
QUADOMICS be easy to apply and consistent, i.e., that
independent users make analogous observations and judgements
when appraising the same study. Accordingly, the primary
objective of this study was to evaluate the applicability and
consistency of the QUADOMICS tool by applying it to a broad
selection of studies in triplicate. An associated secondary objective
was the assessment of the methodological quality of the selection of
recently published ‘-omics’ diagnostic studies, using this tool.
Methods
The study consisted of two parts: 1) the evaluation of the
applicability and consistency of the QUADOMICS tool, and 2)
the evaluation of the methodological quality of a selection of recent
published studies. The same selection of studies was used for both
parts.
Search Strategy
We identified original research articles by a systematic search of
the Pubmed database combining the medical subject headings
(MeSH) ‘‘Genomics’’, ‘‘Sensitivity and specificity’’ and ‘‘Diagno-
sis’’. The search was limited to articles published from 1
st January
2006 through June 17 2009 (the date of the search). The titles and
abstracts of all potential articles were reviewed and articles were
selected based on the following criteria: original research articles in
which the key objective was to evaluate the diagnostic accuracy of
an ‘-omics’ based test for use in clinical practice or a screening
programme (we used the definition of ‘-omics’ applied in the
development of QUADOMICS). [22] Studies which used ‘-omics’
techniques for the discovery of a biomarker pattern but then used
standard laboratory techniques such as immunohistochemistry,
ELISA or PCR to identify the biomarkers and validate the pattern
were not selected. Furthermore, we only selected studies which
presented a diagnostic accuracy measurement (e.g., sensitivity and
specificity, area under ROC curve, diagnostic odds ratio,
likelihood ratios) or that provided enough information for their
calculation. Studies in which the main aim was to validate
biomarkers for prognostic use or to predict the response to
treatment were also excluded, as were articles published in
languages other than English.
Evaluation of the applicability and consistency of the
QUADOMICS tool
Three investigators (LP, NG, BL) independently assessed the
quality of all selected articles using the QUADOMICS tool. For
reference, each reviewer was provided with a copy of the
QUADOMICS publication, [22] the development of QUADAS
publication [21] and the article evaluating QUADAS and
providing some modifications to the items. [29] All three
researchers met to compare their observations and generate the
consensus rating after 8 articles had been reviewed, after 21, and
finally after all 45; any disagreements were solved by discussion.
During this process the authors explored the potential motives for
the lack of agreement and discussed methods to improve the
description of the item in the QUADOMICS guideline in order to
avoid future discrepancies.
To evaluate the consistency of the QUADOMICS tool, we
calculated the percentage agreement between each reviewer’s
original assessment and the consensus rating, both overall and for
each item separately. We chose not to report Cohen’s kappa
statistic for inter-rater agreement because it is strongly influenced
by the prevalence of each rating and can be misleading. [30] We
regarded the consistency as ‘‘low’’ if agreement with the consensus
was less than 60% for at least one reviewer, or if two or more
reviewers had less than 80% agreement with the consensus. The
reasons for limited consistency were evaluated and the item was
reworked if necessary.
Evaluation of the methodological quality of the selected
articles
We used the consensus variables created during the evaluation of
applicability and consistency of QUADOMICS to describe the
methodological quality of the articles. As not all of the items were
applied toeveryarticle(forinstance,somecriteriaareonlyappliedto
articles in phase 4), we summarised the overall quality of each article
by calculating the percentage of applied articles which scored
positively.Finally,toidentifyifcertainmethodologicalshort-comings
QUADOMICS
PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11419were more common than others, we calculated the proportion of
articles which met or failed to meet each item separately.
Data analysis
Univariate descriptive statistics and 95% confidence intervals were
computed as customary. [31,32] All computations were carried out
using STATA/SE 8.0 (StataCorp, College Station, TX, USA).
Results and Discussion
The search strategy provided 164 potential articles, of which 59
were selected for full text revision and 45 were finally selected
(Figure S1). The references of the 45 selected articles can be found
in Annex S1 and a list of the study phase, study size, index test and
reference standard of each study is found in Table S1.
Applicability and consistency of QUADOMICS
Overall, the percentage agreement with the consensus rating was
above 80% for all three reviewers (table 1). Of the 17 quality items,
up to 4 were not applied to some of the articles. These included
items 2 and 14, which should only be applied to studies in phase IV,
as directed in the QUADOMICS background document. [22]
Additionally, items 9 and 13 were only applied to some articles due
to one or both of the following reasons: 1) the index test was almost
exclusively performed after the reference diagnosis, and 2) many
studies did not have an independent reference standard but, rather,
the index test was tested against the diagnosis itself (which was also
the criteria used by the authors to select the patients). For example,
some studies selected a group of patients withthe disease in question
and a group of controls, either healthy individuals or with an
alternative diagnosis. The lack of an independent reference test is a
common problem in studies that seek to validate the diagnostic
application of new ‘-omics’ based technologies and it contributed to
difficulties in the application of the QUADOMICS items that refer
to the reference standard. When possible, we applied these quality
items by considering how and when the initial diagnosis was made,
or how the diagnosis was ruled out in the controls. We decided that
it would be unfair to score studies negatively for all items that
Table 1. Consistency in the application of the QUADOMICS tool to 45 diagnostic ‘-omics’ studies: % agreement with the
consensus
1.
Reviewer 1 Reviewer 2 Reviewer 3
% (95%CI) % (95%CI) % (95%CI)
Study Phase 91.1 (78.8–97.5) 97.8 (88.2–99.9) 73.3 (62.9–88.8)
1. Were selection criteria clearly described? 100 100 100
2. Was the spectrum of patients representative of patients who will
receive the test in practice?
95.2 (84.2–99.4) 100 97.7 (87.7–99.9)
3. Was the type of sample fully described? 86.7 (73.2–94.5) 91.1 (78.8–97.5) 77.8 (87.7–99.9)
4. Were the procedures and timing of biological sample collection
with respect to clinical factors described with enough detail?
4.1. Clinical and physiological factors 86.7 (73.2–94.5) 68.9 (53.2–81.4) 73.3 (58.1–85.4)
4.2. Diagnostic and treatment procedures. 88.9 (75.2–95.8) 86.7 (73.2–94.5) 80.0 (65.4–90.4)
5. Were handling and pre-analytical procedures reported in sufficient
detail and similar for the whole sample? and, if differences in procedures
were reported, was their effect on the results assessed?
64.4 (48.8–78.1) 93.3 (81.7–98.6) 88.9 (75.2–95.8)
6. Is the time period between the reference standard and the
index test short enough to reasonably guarantee that the target
condition did not change between the two tests?
68.9 (53.2–81.4) 84.4 (70.5–93.5) 53.3 (37.9–68.3)
7. Is the reference standard likely to correctly classify the target condition? 80.0 (65.4–90.4) 88.9 (75.2–95.8) 64.4 (48.8–78.3)
8. Did the whole sample or a random selection of the sample
receive verification using a reference standard of diagnosis?
80.0 (65.4–90.4) 93.3 (81.7–98.6) 73.3 (58.1–85.4)
9. Did patients receive the same reference standard regardless of the
result of the index test?
80.0 (65.4–90.4) 82.2 (67.9–92.0) 97.8 (88.2–99.9)
10. Was the execution of the index test described in sufficient
detail to permit replication of the test?
84.4 (70.5–93.5) 77.8 (87.7–99.9) 88.9 (75.2–95.8)
11. Was the execution of the reference standard described in
sufficient detail to permit its replication?
77.8 (87.7–99.9) 80.0 (65.4–90.4) 62.2 (46.5–76.2)
12. Were the index test results interpreted without knowledge
of the results of the reference standard?
88.9 (75.2–95.8) 91.1 (78.8–97.5) 91.1 (78.8–97.5)
13. Were the reference standard results interpreted without
knowledge of the results of the index test?
88.9 (75.2–95.8) 97.8 (88.2–99.9) 100
14. Were the same clinical data available when test results were i
nterpreted as would be available when the test is used in practice?
97.6 (87.4–99.9) 100 100
15. Were uninterpretable/intermediate test results reported? 57.8 (42.2–72.0) 93.3 (81.7–98.6) 73.3 (58.1–85.4)
16. Is it likely that the presence of overfitting was avoided? 73.3 (58.1–85.4) 93.3 (81.7–98.6) 84.4 (70.5–93.5)
Overall 83.0 (80.2–85.5) 89.9 (87.5–91.9) 82.3 (79.5–84.9)
1A consensus rating was achieved by discussion between the three reviewers for every item of each study separately.
doi:10.1371/journal.pone.0011419.t001
QUADOMICS
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to the biases addressed by every quality item.
When each item was analysed individually, four items -4.1, 6, 11
and 15- showed a low consistency according to our definition (one
reviewer with less than 60% agreement with consensus, or 2+
reviewers with less than 80%). The motives for limited agreement
are next discussed individually for each item.
Item 4.1: Were the procedures and timing of biological
sample collection with respect to clinical factors described
with enough detail? -Clinical and pathophysiological
factors. There was some disagreement as to what constituted
‘enough detail’.Reporting sex and age of the patientsina descriptive
table should not be considered sufficient to score positively. Ideally,
authors should perform an analysis of the influence of procedures
and timing of biological sample collection on the results of the test
(example excerpt below). Nevertheless, in this review it was decided
that studies scored positively as long as they provided some
additional clinical information (apart from sex and age), such as
cancer stage. It is advised that, before carrying out a systematic
review, the authors discuss what is considered to be ‘enough detail’.
Example. Score positively:
‘‘… was employed to determine whether potentially confounding clinical
variables such as patient age, sex, time from transplantation, HCV
status, immunosuppressive therapy (…), and peripheral blood monocyte,
lymphocyte, and neutrophil counts could be influencing gene-expression
levels.’’ [No. 17 in Annex S1]
Item 6: Is the time period between the reference standard
and the index test short enough to reasonably guarantee
that the target condition did not change between the two
tests? As discussed, most studies in ‘-omics’ technologies selected
patientswithestablisheddiagnosisandacontrolgroup,andusedthis
classification as the reference standard. Thus, to evaluate disease
progression bias [33] one should consider the time period between
the initial diagnosis of the established condition and performance of
the index test. This item is especially relevant for proteomics-based
tests when the biomarker profile may be considerably different at
differentstagesindisease. To score positively the diagnosis should be
confirmed at the time of sample collection, and the disease stage
should be noted or the time since diagnosis should be stated, so that
disease progression bias can be evaluated (example excerpts below).
If the authors fail to mention time since diagnosis this item should be
marked unclear. If the authors mention time since diagnosis but the
reviewer considers it to be too long (refer to QUADAS), [21] this
item should be scored as no. If the test is based on a DNA
microarray it is unlikely to be affected by the time since diagnosis
a n ds ot h i si t e mw i l lb es c o r e da sy e s .
Example. Score positively:
‘‘At the time the sample was taken, all patients were classified by the
clinician, according to standard criteria, as having active or inactive
renal or systemic lupus.’’ [No. 22 in Annex S1] or ‘‘The clinical
stage distribution of the 132 patients was as follows: stage I (n=16);
stage II (n=56); stage III (n=44); and stage IV (n=16).’’
[No. 43 in Annex S1]
Example. Score unclear:
‘‘Sera from pathologically confirmed lung cancer and benign tobacco-
induced or tobacco-associated chronic lung disease patients were
collected…’’ [No. 12 in Annex S1]
Item 11: Was the execution of the reference standard
described in sufficient detail to permit its replication? The
application of this item was made more complicated by the absence
of an independent reference test in many of the studies. We
evaluated whether the diagnostic criteria which gave rise to patient
selection were described in enough detail. On several occasions, the
diagnostic process for the cases with the disease of interest was
described in sufficient detail; yet, there was relatively little
information relating to how the authors established the absence of
disease in the comparison group. Consistency was limited for this
item because the reviewers dealt with this situation differently. We
recommend that before carrying out a review, the authors discuss
firstly whether they want to include studies that use prior diagnoses
as the reference diagnosis, and secondly, if they choose to include
them, what information should be given as a minimum to rule out
the disease in the comparison group.
Item 15: Were uninterpretable/intermediate test results
reported? We experienced difficulties in evaluating this item as
few studies mentioned uninterpretable results. We sought to apply
the modification to this item made in the evaluation of QUADAS.
‘‘If the authors do not report any uninterpretable/indeterminate/intermediate
results, and if results are reported for all patients who were described as having
been entered into the study then this item should also be scored as ‘‘yes’’. [21]
Nevertheless, problems arose because it was difficult to judge if all
patients described as having entered into the study contributed to
the results presented, as often authors reported the diagnostic
accuracy for different biomarker patterns (e.g., different protein
peaks), without actually providing the crude patient numbers
(example excerpt below). It was agreed that in this case we would
mark the item ‘‘unclear’’.
Example. Score positively:
‘‘…the test group had 52 patients and 33 controls.’’ R ‘‘Analyses of
the spectra from the 85 testing samples showed that the classification
algorithm correctly predicted 94% (80 of 85) of all of the samples,
with 94% (49 of 52) of DLBCL samples and 94% (31 of 33) of the
control samples. The specificity was 94% and the sensitivity was
94%.’’ [No. 43 in Annex S1]
Example. Score unclear:
‘‘Cancers (62 samples) and controls (31 samples) were collected into
identical tubes and processed in an identical manner.’’ R ‘‘Varying
numbers of the most significant peaks were then used to develop ANNs to
discriminate between cancer and non-cancer with 10-fold cross-
validation. The ANNs developed using the seven most significant peaks
performed best giving a sensitivity of 94% and specificity of 96%.’’
[No. 37 in Annex S1]
Quality of selected articles
Out of 45 included articles, 35 were considered to be in phase 1
(78%). Only 6 articles (13.3%) reflected the clinical situation in
which the test would be used in practice, phase 4. This finding has
important implications given that the case-control design used in
phases I-III can lead to an overestimation of diagnostic accuracy.
[34,35]
There were 15 (33.3%) studies published in 2008, 13 (28.9%)
each in 2006 and 2007, and 4 (8.9%) in 2009.
It is worth mentioning that the main goal in developing
QUADOMICS, like QUADAS, was not for assessing the absolute
quality in a cross-sectional sample of studies examining different
QUADOMICS
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in systematic reviews to identify differences in design and conduct
that could lead to bias or variation in accuracy within a set of
studies examining the same index test. Nevertheless, we have
outlined how QUADOMICS can be tailored to suit the different
phases of development and in such, any methodological
shortcoming highlighted in our analysis was relevant considering
the stage of development. Accordingly, up to four items were not
applied to some of the selected articles and we evaluated the
absolute quality of the studies by calculating the proportion of
applied criteria that scored positively.
There was substantial variation in the number of quality criteria
met by the selected articles, with one article meeting only 2 of 13
applied criteria (15.4%), [36] and another meeting 12 of 13
applied criteria (92.3%). [37]On average, the selected studies
scored positively in just over half of the applied criteria (mean 6
standard deviation, 54.7618.4%). We have reported the percent-
age of applied criteria which scored positively to summarise the
quality of the studies only. We do not believe that a critical
threshold should be used when judging study quality [38]. We
provide QUADOMICS as a tool that allows systematic reviewers
and other readers to identify potential methodological weaknesses
in a study, which could have biased the diagnostic accuracy, and
therefore judge themselves whether study results are valid. The use
of a critical threshold would not appropriately distinguish between
a study with a single methodological shortcoming that completely
invalidates the results, and a study that does not properly address a
number of less influential items.
That being said, the methodological quality of the articles was
generally poor, with numerous studies failing to address critical
details. This in itself is a relevant finding because high quality
studies are imperative if we are to ensure that the application of ‘-
omics’ based diagnostic tests to clinical practice is evidence based.
To identify the most common methodological short-comings, we
explored the proportion of articles that met or failed to meet each
item separately (Table 2). The most relevant findings are discussed
in more detail below.
Aspects relating to the patient population and samples
studied (Items 1–5). In general, the description of the sample
population was poor and none of the articles scored positively for
item 1 due to the absence of a flow diagram describing the flow of
patients in the selection process. The limited description of the
patient population observed in these studies was disconcerting as
this information is essential in order to assess external validity.
Interestingly, even one of the phase 4 studies, scored negatively for
the item on patient spectrum (item 2, example excerpt below).
This study sought to validate a proteomics based urine test for the
diagnosis of ovarian cancer. [39] Although it was considered to be
phase 4 due to the inclusion of a consecutive series of patients, it is
likely that by selecting women undergoing surgery the study
selected a more severely diseased patient population than would
normally receive the urine based test:
Table 2. Evaluation of the methodological quality of 45 diagnostic ‘-omics’ studies using the QUADOMICS tool.
Item Yes (%) No (%) Unclear (%) N/A (%)
1. Were selection criteria clearly described? 0 — 45 (100) 0 — 0 —
2. Was the spectrum of patients representative of patients
who will receive the test in practice?
4 (8.9) 1 (2.2) 1 (2.2) 39 (86.7)
3. Was the type of sample fully described? 40 (88.9) 4 (8.9) 1 (2.2) 0 —
4. Were the procedures and timing of biological sample collection
with respect to clinical factors described with enough detail?
4.1. Clinical and physiological factors 20 (44.4) 25 (55.6) 0 — 0 —
4.2. Diagnostic and treatment procedures. 22 (48.9) 22 (48.9) 1 (2.2) 0 —
5. Were handling and pre-analytical procedures reported in sufficient
detail and similar for the whole sample? and, if differences in
procedures were reported, was their effect on the results assessed?
38 (84.4) 7 (15.6) 0 — 0 —
6. Is the time period between the reference standard and the
index test short enough to reasonably guarantee that the target
condition did not change between the two tests?
20 (44.4) 1 (2.2) 24 (53.3) 0 —
7. Is the reference standard likely to correctly classify the target condition? 33 (73.3) 6 (13.3) 6 (13.3) 0 —
8. Did the whole sample or a random selection of the sample
receive verification using a reference standard of diagnosis?
24 (53.3) 14 (31.1) 7 (15.6) 0 (0.0)
9. Did patients receive the same reference standard regardless
of the result of the index test?
1 (2.2) 0 — 0 — 44 (97.8)
11. Was the execution of the reference standard described in
sufficient detail to permit its replication?
21 (46.7) 24 (53.3) 0 — 0 —
12. Were the index test results interpreted without knowledge
of the results of the reference standard?
20 (44.4) 25 (55.6) 0 — 0 —
13. Were the reference standard results interpreted without
knowledge of the results of the index test?
6 (13.3) 0 — 0 — 39 (86.7)
14. Were the same clinical data available when test results were
interpreted as would be available when the test is used in practice?
5 (11.1) 1 (2.2) 0 — 39 (86.7)
15. Were uninterpretable/intermediate test results reported? 33 (73.3) 2 (4.4) 10 (22.2) 0 —
16. Is it likely that the presence of overfitting was avoided? 20 (44.4) 22 (48.9) 3 (6.7) 0 —
doi:10.1371/journal.pone.0011419.t002
QUADOMICS
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‘‘Urine samples and paired blood samples were prospectively collected
from 209 consecutive women admitted for an exploratory laparotomy for
an ovarian neoplasm at the Gynaecological Department at Rigshospita-
let, Copenhagen between June 2006 and August 2007.’’ [No. 25 in
Annex S1]
Only half of the studies considered the diagnostic or treatment
procedures undergone by the patient before the sample was taken
(Item 4.2: 22, 49.9%), and even fewer described the clinical and
pathophysiological factors that might influence the biomarker
profile [13,14] (Item 4.1: 20 studies, 44.4%). Most articles clearly
described the type of sample used and the pre-analytical
procedures in sample preparation (Item 3: 40, 88.9%, Item 5:
38, 84.4%).
Aspects relating to the test being evaluated (Items 10, 13,
14). 19 (42.2%) studies did not describe the index test in enough
detail (Item 10). Less than half of the studies (Item 13: 20, 44.4%)
mentioned whether the index test result was interpreted without
knowledge of the reference standard; such omission suggests that
review bias was possible. [19,26] On the other hand, one of the
phase 4 studies was subject to a kind of over blinding, and scored
negatively in item 14 (example excerpt below). This study
evaluated a gene expression profile for the identification of the
tissue of origin in the case of metastatic, poorly differentiated
specimens. [40] Although blinding of the reference diagnosis is
necessary to avoid review bias, in clinical practice the clinician
interpreting the test would have access to details such as patient
sex and tumour pathology.
Example. ‘‘… investigators who interpreted the Pathwork Tissue of
Origin Test results for making a tissue determination were blinded to
patient sex, histology, or morphology information, and reference
diagnosis’’ [No. 21 in Annex S1]
Aspects relating to the reference test (Items 6, 11). Over
half of the articles did not describe the reference test in enough
detail (Item 11: 21, 46.7%). As mentioned earlier many of the
articles did not actually include an independent reference test. In
this case we evaluated the diagnosis of the target condition or
selection criteria for the comparison group. Furthermore, over half
of the articles failed to mention any time period with regard to
diagnosis, making it difficult to judge whether the target condition
could have changed (item 6: 24, 53.3% unclear).
Overfitting (Item 16). 22 (48.9%) studies did not effectively
control for overfitting, and in 3 studies (6.7%) it was not clear if
validation was carried out in samples from the same patients in
which the model was built. Only studies that validated their
biomarker signature in an independent set of patient samples
scored positively for this item; i.e., studies that performed internal
validation using cross validation alone did not score positively. We
deem this an important finding because it is likely that the results
presented in these studies are overly optimistic [41] and may not
be reproducible in other patient populations. [42]
Finally, there was no apparent change in the proportion of
studies meeting each item separately over the 4 years studies (data
not shown), but numbers were small.
Conclusions
In this study we showed that three reviewers could apply the
QUADOMICS tool to a broad sample of diagnostic ‘-omics’ studies
with reasonable consistency. A small number of items were difficult
to apply to studies that did not use an independent test for
determining the reference diagnosis. This problem with item
applicability arose in studies which used a healthy or alternative
diagnosis comparison group and, thus, it was closely linked to the
study phase of the articles (phases I–III). On one hand, the
importance of this problem is limited because systematic reviews
and meta-analyses carried out to inform decision makers of the
evidence supporting the use of a test in clinical practice should focus
on studies with more clinically relevant populations (phase IV). On
the other hand, it is highly important that the quality of early phase
studies is adequately assessed in order to weigh up the evidence and
decide if it is a sensible use of resources to proceed to studies in more
clinically relevant populations. Here, we have outlined how the
QUADOMICS criteria can be applied to these studies.
In practice the QUADOMICS guideline will be used to
evaluate studies included in a systematic review and, therefore,
studies should all be addressing the same diagnostic question, and
be in the same phase. Similar to QUADAS, [21] reviewers should
tailor the guideline to suit their specific review question. For
example, if they want to assess the utility of the test for use in
clinical practice, they should only include phase IV studies, and
make some decisions before evaluating the studies (e.g., what
should be the appropriate reference standard, how much
information is considered to be ‘sufficient detail’ or how long is
too long for the time period between reference and index test). On
the other hand, a review carried out to assess the preliminary
evidence in favour of a new ‘-omics’ test in order to judge whether
it would be sensible or appropriate to carry out a large scale
prospective evaluation may include studies from earlier phases
which use the case-control type design. While it would extremely
important to consider differences between the two diagnostic
groups with regard to pre-analytical conditions (item 5), or the
clinical characteristics of the patients providing samples (item 4), it
would be inappropriate to score a study negatively because it does
not meet item 2 (‘Was the spectrum of patients representative of
patients who will receive the test in practice?’). In this case the
tailoring of the guideline would involve eliminating the items that
are not applicable as well as making decisions as how specific items
should be scored. By applying QUADOMICS to a broad range of
articles from different subjects, we have shown that it is flexible,
and we believe that the ability to be tailored to the different study
phases is one of its key strengths.
The methodological quality of our selection of 45 ‘-omics’ based
diagnostic studies was poor. It is alarming, for example, that none
of the studies included a flow diagram describing the patient
recruitment process; such diagrams are also strongly recommend-
ed in the Standards for Reporting of Diagnostic Accuracy
(STARD) publication. [43] This deficiency is not specific to the
‘-omics’ field; for instance, a recent review of commercial tests for
HIV, TB or malaria showed that only 13% of studies reviewed
met the STARD criterion which recommends the flow diagram.
[44] This issue is in fact a reporting item and therefore only
indirectly linked to quality. Studies that meet this criterion do not
automatically have clinically relevant populations, yet in studies
that do not clearly describe patient recruitment it is impossible to
evaluate whether the results are applicable to our context. It is
arguable that reporting items have no place in instruments
measuring methodological quality however, despite increased
sensitisation to issues related to the quality of reporting, diagnostic
research remains poorly reported [45] and evaluating methodo-
logical quality relies on transparent and good quality reporting. In
such we feel that such items do help draw attention of the readers
to potential methodological limitations, and thus reduce assump-
tions that the methodology was sound.
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instance, it is now recognised that patient treatment regimes or
other clinical and pathophysiological characteristics may influence
the parameters studied, such as proteins, and thus bias ‘-omics’
studies. [13,14,46,47] Nevertheless, few of the studies we assessed
actually reported these details, let alone analysed their potential
effect. Furthermore, in nearly half of the articles the diagnostic
model was not validated in an independent set of patients; such
shortfall may lead to overfitting and the production of results that
are not reproducible. Coupled with the fact that very few of the
studies were actually carried out in a consecutive set of patients
with clinical suspicion of the disease in question, the problem
illustrates the relative lack of attention paid in ‘-omics’ research to
design issues that are fundamental when we aim at making
inferences relevant for patient care.
One limitation of this study is the external validity of our
assessment of the quality of recent articles published in this field,
our secondary objective. We do not presume to have included all
diagnostic ‘-omics’ studies published in 2006 through 2009. While
our sample was not restricted to any particular field or technique,
it is clear that it was limited to reports indexed by Medline, and
adequately tagged with the selected MeSH terms. Nevertheless for
our primary objective, we feel that the selected sample was
sufficiently diverse to adequately assess the applicability and
consistency of the QUADOMICS tool.
Another issue is related to the three reviewers used to evaluate
the consistency and applicability of QUADOMICS. While the
three reviewers had different backgrounds and varying levels of
research experience, in principle it would have been beneficial to
include a larger number of reviewers with a wider knowledge of
the diseases of interest. Furthermore, two of the three observers
were involved in the development of the tool, and hence may have
found the tool easier to apply. However, in practice QUADO-
MICS will be used to evaluate the quality of studies addressing the
same diagnostic question and reviewers will decide a priori how
each item should be scored. In such situations it is likely that
application would be more straightforward and that reviewer
observations would be more consistent. Here we provide an
evaluation of the tool in general, rather than for every subject
separately, because at this stage in the development of QUADO-
MICS, we felt it was important to ensure the tool was applicable to
a broad range of real studies.
For ethical, clinical and economic reasons, the application of ‘-
omics’ based tests in clinical practice requires valid and reliable
research that can be reproduced in clinically relevant patient
populations. [23–25] While some of the methodological deficien-
cies we described were linked to the specific peculiarities of ‘-
omics’ based research, other important aspects -which have long
been considered fundamental in traditional diagnostic research,
such as the description of the index test and test reproducibility-
are being overlooked in ‘-omics’ research. The QUADOMICS
tool was proposed for the assessment of the methodological quality
of diagnostic research using ‘-omics’ based technology. [22] We
show that the tool can consistently be applied to a broad range of
these studies. Furthermore, we hope that it will help sensitize
researchers, clinicians and other decision makers to the serious
threats to the validity inherent to this type of research, and
ensure that the provision of ‘-omics’ tests to the clinic is evidence
based.
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